AtoxBio
Ceo: Dan Teleman
Year Established: 2003
AtoxBio is a late-stage biotechnology company that develops novel immunomodulators for critically ill patients.
Reltecimod, AtoxBio’s lead product, is initially being developed to treat Necrotizing Soft Tissue Infections (NSTI), a rare, life-threatening infection with high morbidity and mortality.
Reltecimod is currently being studied in ACCUTE (Reltecimod Clinical Composite endpoint Study in necrotizing soft Tissue InfEctions), a phase 3 clinical trial evaluating its efficacy in patients with NSTI. Previously, Reltecimod completed a phase 2 study in NSTI. Results demonstrated that patients treated with Reltecimod had a meaningful improvement across multiple endpoints.
